Iterum Therapeutics非GAAP每股收益为-0.10美元

2025-05-13 19:05

Iterum Therapeutics press release (NASDAQ:ITRM): Q1 Non-GAAP EPS of -$0.10.
Cash and cash equivalents were $12.7 million as of March 31, 2025. Based on Iterum’s current operating plan, Iterum expects that its cash and cash equivalents as of March 31, 2025, together with $1.0 million of net proceeds raised under its at-the-market offering program from April 1, 2025 through April 22, 2025 and net proceeds of $4.2 million from the Registered Direct Offering that closed April 30, 2025, will be sufficient to fund its operations into 2026.

More on Iterum Therapeutics